RecruitingPhase 3NCT07174427
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Studying Synovial sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takara Bio Inc.
- Intervention
- TBI-1301(biological)
- Enrollment
- 5 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2032
Study locations (2)
- Osaka International Cancer Institute, Osaka, Osaka, Japan
- Kyusyu University Hospital, Fukuoka, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07174427 on ClinicalTrials.govOther trials for Synovial sarcoma
Additional recruiting or active studies for the same condition.